Pentoxifylline for Treatment of Resistant Major Depression
Status:
Completed
Trial end date:
2022-04-04
Target enrollment:
Participant gender:
Summary
A growing body of evidence has highlighted the role of inflammation and phosphodiesterases
(PDE)-related pathways in the pathogenesis of neuropsychiatric illnesses such as
depression/mood disorders. Herein, we aimed to evaluate the therapeutic benefits of
pentoxifylline (PTX) in the treatment of therapy-resistant depression (TRD) in adult patients
with bipolar depression.